المؤلفون: Brima Musa Younis, Ahmed Mudawi Musa, Séverine Monnerat, Mohammed Abdelrahim Saeed, Eltahir Awad Gasim Khalil, Anas Elbashir Ahmed, Mujahid Ahmed Ali, Ali Noureldin, Gina Muthoni Ouattara, Godfrey M. Nyakaya, Samuel Teshome, Truphosa Omollo, Michael Ochieng, Thaddaeus Egondi, Mildred Mmbone, Wan-Yu Chu, Thomas P. C. Dorlo, Eduard E. Zijlstra, Monique Wasunna, Jorge Alvar, Fabiana Alves

مصطلحات موضوعية: Medicine, Pharmacology, Biotechnology, Cancer, Infectious Diseases, Virology, Computational Biology, liposomal amphotericin b, future vl elimination, either daily intra, azar dermal leishmaniasis, 2 %, 3 &# 8211, 2 &# 8211, 0 %, 110 patients completed, 0 &# 8211, actual treatment received, grade 3 pkdl, least one dose, plus oral miltefosine, mf &# 8211, additional pkdl treatment, randomized patients receiving, currently recommended 60, 6 %) patients, 12 years old, +treatment%22">xlink "> treatment, safe oral therapies

Time: 95

Relation: https://figshare.com/articles/journal_contribution/CONSORT_2010_checklist_of_information_to_include_when_reporting_a_randomised_trial_/24601630

الاتاحة: https://doi.org/10.1371/journal.pntd.0011780.s003
https://figshare.com/articles/journal_contribution/CONSORT_2010_checklist_of_information_to_include_when_reporting_a_randomised_trial_/24601630

المؤلفون: Brima Musa Younis, Ahmed Mudawi Musa, Séverine Monnerat, Mohammed Abdelrahim Saeed, Eltahir Awad Gasim Khalil, Anas Elbashir Ahmed, Mujahid Ahmed Ali, Ali Noureldin, Gina Muthoni Ouattara, Godfrey M. Nyakaya, Samuel Teshome, Truphosa Omollo, Michael Ochieng, Thaddaeus Egondi, Mildred Mmbone, Wan-Yu Chu, Thomas P. C. Dorlo, Eduard E. Zijlstra, Monique Wasunna, Jorge Alvar, Fabiana Alves

مصطلحات موضوعية: Medicine, Pharmacology, Biotechnology, Cancer, Infectious Diseases, Virology, Computational Biology, liposomal amphotericin b, future vl elimination, either daily intra, azar dermal leishmaniasis, 2 %, 3 &# 8211, 2 &# 8211, 0 %, 110 patients completed, 0 &# 8211, actual treatment received, grade 3 pkdl, least one dose, plus oral miltefosine, mf &# 8211, additional pkdl treatment, randomized patients receiving, currently recommended 60, 6 %) patients, 12 years old, +treatment%22">xlink "> treatment, safe oral therapies

Time: 95

Relation: https://figshare.com/articles/journal_contribution/PKDL_Sudan_Study_Synopsis_/24601627

الاتاحة: https://doi.org/10.1371/journal.pntd.0011780.s002
https://figshare.com/articles/journal_contribution/PKDL_Sudan_Study_Synopsis_/24601627

المؤلفون: Brima Musa Younis, Ahmed Mudawi Musa, Séverine Monnerat, Mohammed Abdelrahim Saeed, Eltahir Awad Gasim Khalil, Anas Elbashir Ahmed, Mujahid Ahmed Ali, Ali Noureldin, Gina Muthoni Ouattara, Godfrey M. Nyakaya, Samuel Teshome, Truphosa Omollo, Michael Ochieng, Thaddaeus Egondi, Mildred Mmbone, Wan-Yu Chu, Thomas P. C. Dorlo, Eduard E. Zijlstra, Monique Wasunna, Jorge Alvar, Fabiana Alves

مصطلحات موضوعية: Medicine, Pharmacology, Biotechnology, Cancer, Infectious Diseases, Virology, Computational Biology, liposomal amphotericin b, future vl elimination, either daily intra, azar dermal leishmaniasis, 2 %, 3 &# 8211, 2 &# 8211, 0 %, 110 patients completed, 0 &# 8211, actual treatment received, grade 3 pkdl, least one dose, plus oral miltefosine, mf &# 8211, additional pkdl treatment, randomized patients receiving, currently recommended 60, 6 %) patients, 12 years old, +treatment%22">xlink "> treatment, safe oral therapies

Time: 95

Relation: https://figshare.com/articles/journal_contribution/Supplementary_material_/24601538

الاتاحة: https://doi.org/10.1371/journal.pntd.0011780.s001
https://figshare.com/articles/journal_contribution/Supplementary_material_/24601538

المؤلفون: Brima Musa Younis, Ahmed Mudawi Musa, Séverine Monnerat, Mohammed Abdelrahim Saeed, Eltahir Awad Gasim Khalil, Anas Elbashir Ahmed, Mujahid Ahmed Ali, Ali Noureldin, Gina Muthoni Ouattara, Godfrey M. Nyakaya, Samuel Teshome, Truphosa Omollo, Michael Ochieng, Thaddaeus Egondi, Mildred Mmbone, Wan-Yu Chu, Thomas P. C. Dorlo, Eduard E. Zijlstra, Monique Wasunna, Jorge Alvar, Fabiana Alves

مصطلحات موضوعية: Medicine, Pharmacology, Biotechnology, Cancer, Infectious Diseases, Virology, Computational Biology, liposomal amphotericin b, future vl elimination, either daily intra, azar dermal leishmaniasis, 2 %, 3 &# 8211, 2 &# 8211, 0 %, 110 patients completed, 0 &# 8211, actual treatment received, grade 3 pkdl, least one dose, plus oral miltefosine, mf &# 8211, additional pkdl treatment, randomized patients receiving, currently recommended 60, 6 %) patients, 12 years old, +treatment%22">xlink "> treatment, safe oral therapies

Time: 95

Relation: https://figshare.com/articles/figure/Fig_1_-/24601636

الاتاحة: https://doi.org/10.1371/journal.pntd.0011780.g001
https://figshare.com/articles/figure/Fig_1_-/24601636

المؤلفون: Brima Musa Younis, Ahmed Mudawi Musa, Séverine Monnerat, Mohammed Abdelrahim Saeed, Eltahir Awad Gasim Khalil, Anas Elbashir Ahmed, Mujahid Ahmed Ali, Ali Noureldin, Gina Muthoni Ouattara, Godfrey M. Nyakaya, Samuel Teshome, Truphosa Omollo, Michael Ochieng, Thaddaeus Egondi, Mildred Mmbone, Wan-Yu Chu, Thomas P. C. Dorlo, Eduard E. Zijlstra, Monique Wasunna, Jorge Alvar, Fabiana Alves

مصطلحات موضوعية: Medicine, Pharmacology, Biotechnology, Cancer, Infectious Diseases, Virology, Computational Biology, liposomal amphotericin b, future vl elimination, either daily intra, azar dermal leishmaniasis, 2 %, 3 &# 8211, 2 &# 8211, 0 %, 110 patients completed, 0 &# 8211, actual treatment received, grade 3 pkdl, least one dose, plus oral miltefosine, mf &# 8211, additional pkdl treatment, randomized patients receiving, currently recommended 60, 6 %) patients, 12 years old, +treatment%22">xlink "> treatment, safe oral therapies

Time: 95

Relation: https://figshare.com/articles/figure/PKDL_lesion_distribution_grade_over_time_by_treatment_arm_mITT_set_/24601642

الاتاحة: https://doi.org/10.1371/journal.pntd.0011780.g003
https://figshare.com/articles/figure/PKDL_lesion_distribution_grade_over_time_by_treatment_arm_mITT_set_/24601642

المؤلفون: Brima Musa Younis, Ahmed Mudawi Musa, Séverine Monnerat, Mohammed Abdelrahim Saeed, Eltahir Awad Gasim Khalil, Anas Elbashir Ahmed, Mujahid Ahmed Ali, Ali Noureldin, Gina Muthoni Ouattara, Godfrey M. Nyakaya, Samuel Teshome, Truphosa Omollo, Michael Ochieng, Thaddaeus Egondi, Mildred Mmbone, Wan-Yu Chu, Thomas P. C. Dorlo, Eduard E. Zijlstra, Monique Wasunna, Jorge Alvar, Fabiana Alves

مصطلحات موضوعية: Medicine, Pharmacology, Biotechnology, Cancer, Infectious Diseases, Virology, Computational Biology, liposomal amphotericin b, future vl elimination, either daily intra, azar dermal leishmaniasis, 2 %, 3 &# 8211, 2 &# 8211, 0 %, 110 patients completed, 0 &# 8211, actual treatment received, grade 3 pkdl, least one dose, plus oral miltefosine, mf &# 8211, additional pkdl treatment, randomized patients receiving, currently recommended 60, 6 %) patients, 12 years old, +treatment%22">xlink "> treatment, safe oral therapies

Time: 95

Relation: https://figshare.com/articles/dataset/Primary_efficacy_outcome_of_definitive_cure_at_12_months_by_treatment_arm_mITT_and_PP_sets_/24601651

الاتاحة: https://doi.org/10.1371/journal.pntd.0011780.t002
https://figshare.com/articles/dataset/Primary_efficacy_outcome_of_definitive_cure_at_12_months_by_treatment_arm_mITT_and_PP_sets_/24601651

المؤلفون: Brima Musa Younis, Ahmed Mudawi Musa, Séverine Monnerat, Mohammed Abdelrahim Saeed, Eltahir Awad Gasim Khalil, Anas Elbashir Ahmed, Mujahid Ahmed Ali, Ali Noureldin, Gina Muthoni Ouattara, Godfrey M. Nyakaya, Samuel Teshome, Truphosa Omollo, Michael Ochieng, Thaddaeus Egondi, Mildred Mmbone, Wan-Yu Chu, Thomas P. C. Dorlo, Eduard E. Zijlstra, Monique Wasunna, Jorge Alvar, Fabiana Alves

مصطلحات موضوعية: Medicine, Pharmacology, Biotechnology, Cancer, Infectious Diseases, Virology, Computational Biology, liposomal amphotericin b, future vl elimination, either daily intra, azar dermal leishmaniasis, 2 %, 3 &# 8211, 2 &# 8211, 0 %, 110 patients completed, 0 &# 8211, actual treatment received, grade 3 pkdl, least one dose, plus oral miltefosine, mf &# 8211, additional pkdl treatment, randomized patients receiving, currently recommended 60, 6 %) patients, 12 years old, +treatment%22">xlink "> treatment, safe oral therapies

Time: 95

Relation: https://figshare.com/articles/figure/Median_plasma_and_skin_concentrations_of_miltefosine_on_days_28_and_42_of_paromomycin_on_day_14_and_liposomal_amphotericin_B_on_day_7_/24601645

الاتاحة: https://doi.org/10.1371/journal.pntd.0011780.g004
https://figshare.com/articles/figure/Median_plasma_and_skin_concentrations_of_miltefosine_on_days_28_and_42_of_paromomycin_on_day_14_and_liposomal_amphotericin_B_on_day_7_/24601645

المؤلفون: Brima Musa Younis, Ahmed Mudawi Musa, Séverine Monnerat, Mohammed Abdelrahim Saeed, Eltahir Awad Gasim Khalil, Anas Elbashir Ahmed, Mujahid Ahmed Ali, Ali Noureldin, Gina Muthoni Ouattara, Godfrey M. Nyakaya, Samuel Teshome, Truphosa Omollo, Michael Ochieng, Thaddaeus Egondi, Mildred Mmbone, Wan-Yu Chu, Thomas P. C. Dorlo, Eduard E. Zijlstra, Monique Wasunna, Jorge Alvar, Fabiana Alves

مصطلحات موضوعية: Medicine, Pharmacology, Biotechnology, Cancer, Infectious Diseases, Virology, Computational Biology, liposomal amphotericin b, future vl elimination, either daily intra, azar dermal leishmaniasis, 2 %, 3 &# 8211, 2 &# 8211, 0 %, 110 patients completed, 0 &# 8211, actual treatment received, grade 3 pkdl, least one dose, plus oral miltefosine, mf &# 8211, additional pkdl treatment, randomized patients receiving, currently recommended 60, 6 %) patients, 12 years old, +treatment%22">xlink "> treatment, safe oral therapies

Time: 95

Relation: https://figshare.com/articles/figure/Kaplan-Meier_curve_of_time_to_complete_cure_by_treatment_arm_and_overall_mITT_set_/24601639

الاتاحة: https://doi.org/10.1371/journal.pntd.0011780.g002
https://figshare.com/articles/figure/Kaplan-Meier_curve_of_time_to_complete_cure_by_treatment_arm_and_overall_mITT_set_/24601639

المؤلفون: Brima Musa Younis, Ahmed Mudawi Musa, Séverine Monnerat, Mohammed Abdelrahim Saeed, Eltahir Awad Gasim Khalil, Anas Elbashir Ahmed, Mujahid Ahmed Ali, Ali Noureldin, Gina Muthoni Ouattara, Godfrey M. Nyakaya, Samuel Teshome, Truphosa Omollo, Michael Ochieng, Thaddaeus Egondi, Mildred Mmbone, Wan-Yu Chu, Thomas P. C. Dorlo, Eduard E. Zijlstra, Monique Wasunna, Jorge Alvar, Fabiana Alves

مصطلحات موضوعية: Medicine, Pharmacology, Biotechnology, Cancer, Infectious Diseases, Virology, Computational Biology, liposomal amphotericin b, future vl elimination, either daily intra, azar dermal leishmaniasis, 2 %, 3 &# 8211, 2 &# 8211, 0 %, 110 patients completed, 0 &# 8211, actual treatment received, grade 3 pkdl, least one dose, plus oral miltefosine, mf &# 8211, additional pkdl treatment, randomized patients receiving, currently recommended 60, 6 %) patients, 12 years old, +treatment%22">xlink "> treatment, safe oral therapies

Time: 95

Relation: https://figshare.com/articles/dataset/Baseline_characteristics_by_treatment_arm_and_overall_ITT_set_/24601648

الاتاحة: https://doi.org/10.1371/journal.pntd.0011780.t001
https://figshare.com/articles/dataset/Baseline_characteristics_by_treatment_arm_and_overall_ITT_set_/24601648

المؤلفون: Brima Musa Younis, Ahmed Mudawi Musa, Séverine Monnerat, Mohammed Abdelrahim Saeed, Eltahir Awad Gasim Khalil, Anas Elbashir Ahmed, Mujahid Ahmed Ali, Ali Noureldin, Gina Muthoni Ouattara, Godfrey M. Nyakaya, Samuel Teshome, Truphosa Omollo, Michael Ochieng, Thaddaeus Egondi, Mildred Mmbone, Wan-Yu Chu, Thomas P. C. Dorlo, Eduard E. Zijlstra, Monique Wasunna, Jorge Alvar, Fabiana Alves

مصطلحات موضوعية: Medicine, Pharmacology, Biotechnology, Cancer, Infectious Diseases, Virology, Computational Biology, liposomal amphotericin b, future vl elimination, either daily intra, azar dermal leishmaniasis, 2 %, 3 &# 8211, 2 &# 8211, 0 %, 110 patients completed, 0 &# 8211, actual treatment received, grade 3 pkdl, least one dose, plus oral miltefosine, mf &# 8211, additional pkdl treatment, randomized patients receiving, currently recommended 60, 6 %) patients, 12 years old, +treatment%22">xlink "> treatment, safe oral therapies

Time: 95

Relation: https://figshare.com/articles/dataset/Summary_of_treatment_emergent_adverse_events_mITT_set_/24601654

الاتاحة: https://doi.org/10.1371/journal.pntd.0011780.t003
https://figshare.com/articles/dataset/Summary_of_treatment_emergent_adverse_events_mITT_set_/24601654

المؤلفون: Brima Musa Younis, Ahmed Mudawi Musa, Séverine Monnerat, Mohammed Abdelrahim Saeed, Eltahir Awad Gasim Khalil, Anas Elbashir Ahmed, Mujahid Ahmed Ali, Ali Noureldin, Gina Muthoni Ouattara, Godfrey M. Nyakaya, Samuel Teshome, Truphosa Omollo, Michael Ochieng, Thaddaeus Egondi, Mildred Mmbone, Wan-Yu Chu, Thomas P. C. Dorlo, Eduard E. Zijlstra, Monique Wasunna, Jorge Alvar, Fabiana Alves

مصطلحات موضوعية: Medicine, Pharmacology, Biotechnology, Cancer, Infectious Diseases, Virology, Computational Biology, liposomal amphotericin b, future vl elimination, either daily intra, azar dermal leishmaniasis, 2 %, 3 &# 8211, 2 &# 8211, 0 %, 110 patients completed, 0 &# 8211, actual treatment received, grade 3 pkdl, least one dose, plus oral miltefosine, mf &# 8211, additional pkdl treatment, randomized patients receiving, currently recommended 60, 6 %) patients, 12 years old, +treatment%22">xlink "> treatment, safe oral therapies

Time: 95

Relation: https://figshare.com/articles/dataset/Treatment-emergent_ADRs_by_SOC_and_PT_by_treatment_arm_and_overall_mITT_set_/24601657

الاتاحة: https://doi.org/10.1371/journal.pntd.0011780.t004
https://figshare.com/articles/dataset/Treatment-emergent_ADRs_by_SOC_and_PT_by_treatment_arm_and_overall_mITT_set_/24601657